Navigation Links
Haemacure financing receives shareholder consent - Series B Warrants are amended
Date:5/14/2008

he Schedule annexed to this press release sets out: (a) the names and positions of the "insiders" who hold Series B Warrants; and (b) assuming such "insiders" exercise all Series B Warrants and additional warrants held by them, the number and percentage of common shares of Haemacure that each will own.

About Haemacure

Haemacure Corporation is a specialty biotherapeutics company developing high-value human plasma-derived protein products for commercialization. Haemacure's research and development effort is driven by its proprietary plasma protein extraction technology to develop next-generation products, including surgical hemostats. Haemacure's lead product candidate, Hemaseel(R)HMN, is a fibrin sealant to enter pivotal Phase II/Phase III clinical trials during the first quarter of 2009. Haemacure's second product candidate is thrombin, a component of its fibrin sealant, now in preclinical stage. Follow-on development will focus on surgical hemostats, wound healing, adhesion prevention, regenerative medicine, drug delivery and combinations with biomaterials. Haemacure has discovered eleven additional specialty proteins and enzymes in one of its two plasma fractions and seeks to advance these proteins and enzymes through partnerships with pharmaceutical and biotechnology companies. Haemacure operates offices in Sarasota, Florida through a wholly-owned subsidiary. The Corporation is traded under stock symbol HAE on the TSX.

Forward-looking Statements

Certain of the statements contained in this news release are forward-looking statements. Such statements, based as they are on the current expectations of management, inherently involve numerous risks and uncertainties, known and unknown. Some examples of known risks are: the impact of general economic conditions, general conditions in the biotech industry, changes in the regulatory environment in the jurisdictions in which Haemacure does business, stock market volatility, fluctuations in costs
'/>"/>

SOURCE HAEMACURE CORPORATION
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Haemacure to Present at the BioFinance 2008 Conference to be held at the Toronto Marriott Eaton Centre, May 6 - 8, 2008
2. Haemacure Discloses Positive Results of a preclinical study of its fibrin sealant in adhesion prevention and opens a new opportunity in a market with a significant unmet medical need
3. Haemacure Reports on its annual general and special meeting of shareholders
4. Media Invitation - Annual General and Special Meeting of Shareholders of Haemacure
5. Haemacure Announces Details of its Annual General and Special Meeting of Shareholders
6. Haemacure announces webcast of presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conferencec
7. Haemacure Adopts Strategy for "First-Patient-In" Fibrin Sealant Pivotal Clinical Trials
8. Haemacure Reports Third Quarter 2007 Results
9. InfoLogix Completes $25 Million Senior Debt Financing
10. Cardiva Medical, Inc. Completes $15.5 Million Private Equity Financing
11. Astute Medical Raises $6.2 Million in Series A Financing Round Led by De Novo Ventures
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... According to a recently published report by ... will continue to dominate the European soft tissue reinforcement ... increasing numbers of ventral hernias, and the adoption of ... large market share represented by ventral hernia repair devices ... a growing use of expensive biologics,” explains Dr. Kamran ...
(Date:3/30/2015)... 2015 Vancouver personal injury lawyer firm, ... of cases taken up by the firm are settled ... lawyers help protect the interests of their clients without ... The announcement comes across as an achievement for the ... provide convenience to their client, without compromising their rights. ...
(Date:3/30/2015)... This report studies the global tumor ... to 2019. , Based on the type of ... into four major segments, namely radio-frequency, microwave, cryoablation ... and laser ablation) segments. Moreover, based on type ... classified into three segments, namely, interventional radiology, surgery ...
(Date:3/30/2015)... (PRWEB) March 30, 2015 This ... software market over the forecast period of 2014 ... at a CAGR of 6.5% from 2014 to ... , In this report, the global pharmacovigilance and ... many segments on the basis of functionality, namely, ...
(Date:3/30/2015)... On March 19th, 2015, in the Hall ... Detroit Lions, LiveToBeSober.org hosted the “Fighting Addiction Together” luncheon. ... bishops as well as other civic leaders and public ... luncheon, including retired Detroit Lions wide receiver Herman Moore, ... survivors of their own personal battles with addiction, Ronald ...
Breaking Medicine News(10 mins):Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3Health News:Jiwa Law Corporation States That Majority of Their Cases Get Settled Before Trial 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 2Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 3Health News:The Global Pharmacovigilance and Drug Safety Software Market is Poised to reach the Value of $154.1 Million in 2019 - Report by MarketsandMarkets 4Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2
... Breast Cancer Test MammaPrint(R), AMSTERDAM, the Netherlands, ... Dutch breast cancer test as one of the ... Ball" (MammaPrint(R)) invented and,developed by the International company ... to support the choice of treatment,for that specific ...
... SYNAPT High ... Definition MS System, MILFORD, Mass. ... announced today that the University of,Leeds, Astbury Centre for Structural Molecular ... Waters(R),SYNAPT High Definition MS(TM) (HDMS) System in the Journal of the ...
... WASHINGTON, Dec. 4 In conjunction with,National Handwashing ... Control and Epidemiology presents information on,Methicillin-resistant Staphylococcus aureus ... So what,s the story with MRSA?, MRSA ... and many other,antibiotics. MRSA infections often start as ...
... finds breast cancer patients who lack insurance, who come from ... who are older are less likely to get a key ... those groups are ten percent to three times more likely ... has spread to axillary (underarm) lymph nodes. An abstract of ...
... may not be a more feared dental procedure than a ... is choosing the right professional to perform the procedure. Painful ... to advances pioneered by endodontists, the root canal specialists. In ... of individuals who previously underwent a root canal by an ...
... , TUESDAY, Dec. 4 (HealthDay News) -- Disorganized, meandering tracts ... of dyslexia marked by slow and choppy reading fluency, U.S. ... affects 5 percent to 15 percent of children. , In ... Deaconess Medical Center used a special form of MRI called ...
Cached Medicine News:Health News:Time Magazine Names Agendia Test a Best Invention of 2007 2Health News:In the Forefront of Research into Protein Folding and Macromolecular Complex Assembly 2Health News:In the Forefront of Research into Protein Folding and Macromolecular Complex Assembly 3Health News:In the Forefront of Research into Protein Folding and Macromolecular Complex Assembly 4Health News:In the Forefront of Research into Protein Folding and Macromolecular Complex Assembly 5Health News:In the Forefront of Research into Protein Folding and Macromolecular Complex Assembly 6Health News:MRSA Facts for Handwashing Week 2Health News:Uninsured, others less likely to receive breast cancer test 2Health News:Survey confirms Americans prefer root canal treatment by endodontists 2Health News:Nerve Disorganization May Spur Form of Dyslexia 2
(Date:3/30/2015)... , March 30, 2015  Amgen (NASDAQ: AMGN ) ... conference at 9:05 a.m. ET on Thursday, April 2, 2015, ... York City . Scott Foraker , vice president ... the conference. Live audio of the presentation can be accessed ... under Investors. A replay of the webcast will also be ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/dn2ldn/computer_aided ) ... Aided Detection (CAD) - Global Strategic Business Report" ... estimates and forecasts are provided for the period ... is provided for these markets. Market data and ... Company profiles are primarily based on public domain ...
(Date:3/30/2015)... 30, 2015  Uroplasty, Inc. (NASDAQ: UPI ) ... have voted at the special meeting of each ... announced agreement and plan of merger between the ... the outcome of today,s special meetings, and I ... approving the merger agreement," said Rob Kill ...
Breaking Medicine Technology:Amgen To Present At The Goldman Sachs Key Debates In Biosimilars Conference 2Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 2Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 3Computer Aided Detection (CAD) - Global Strategic Business Report 2015-2020: Rising Incidence of Cancer - A Major Market Driver 4Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 2Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 3Uroplasty and Vision-Sciences Shareholders Approve Merger Agreement 4
... PRINCETON, N.J. , June 21 Celator Pharmaceuticals ... Inc. (Nasdaq: CEPH). The research agreement provides for the utilization of ... program at Cephalon. , ... "We are pleased that work with this research program ...
... Qatar , June 21 One of the leading cancer ... in the region to introduce fast and efficient RapidArc® radiotherapy treatments from ... , has treated nine brain cancer, prostate cancer and head & neck ... now plans to roll out the technology for many more indications. , ...
Cached Medicine Technology:Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 2Celator® Pharmaceuticals Expands Research Agreement With Cephalon, Inc. 3Al Amal Hospital in Qatar Commences Treatments Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Al Amal Hospital in Qatar Commences Treatments Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3
AllMeds was the first specialty-specific Electronic Medical Record for Neurosurgery. Instead of trying to force a general-purpose EMR into your practice, AllMeds starts with clinical content from Neu...
... Optical dispensing is a part of about 40% ... have created a point of sale system. Optical ... program or it can be integrated to the ... national Frames database. Glasses prescriptions, if connected ...
... tasks such as prescription writing, referral letters, ... office will be ,able to add more ... increase staff., Based on the exam documentation ... will recommend the appropriate E&M ,code for ...
... Access your patients' electronic medical ... CardioChart. As a Web-enabled software ... pull up a patient's cardiology ... the hospital intranet. CardioChart displays ...
Medicine Products: